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B-cell chronic lymphocytic leukemia (CLL) is the most common human leukemia occurring as indolent or
aggressive form. CLL clinical features and genetic abnormalities are well documented, but molecular details are still
under investigation. MicroRNAs are small non-coding RNAs involved in several cellular processes and expressed in a
tissue-specific manner. MicroRNAs regulate gene expression, and their deregulation can alter expression levels of
genes involved in development/progression of tumors. In CLL, microRNAs can function as oncogenes or tumor
suppressors and can also serve as markers for CLL onset/progression. Here, we discuss the most recent findings
about the role of microRNAs in CLL and how this knowledge can be used to identify new biomarkers and
treatment approaches.
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Chronic lymphocytic leukemia (CLL) is the most com-
mon human leukemia. This disease can arise in two
forms, aggressive and indolent, both characterized by
the accumulation of incompetent CD5+ B lymphocytes
[1]. Unfavorable prognosis is associated with the expres-
sion of unmutated immunoglobulin heavy variable genes
(UM-IgH-VH) and high level of 70 kD zeta-associated
protein (ZAP-70). Chromosomal alterations are detected
in >80% of cases and can discriminate patients with dif-
ferent outcomes [2,3]: (i) low risk, normal karyotype or
13q deletion; (ii) intermediate risk, 11q deletion or tri-
somy 12; and (iii) high risk, 17p deletion or complex
karyotype [4]. The ability of malignant cells to respond
to microenvironmental stimuli via B-cell receptor (BCR)
signaling, interaction with accessory cells or microvesci-
cles identified in plasma has recently emerged as another
factor in the clinical course of CLL [5,6].Signatures of microRNAs in CLL cells and
microenvironment
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unless otherwise stated.prognosis, progression, and drug resistance [7]. A signa-
ture profile describing 13 microRNAs able to differenti-
ate aggressive and indolent CLL was reported [8].
Patients with high miR-21 and miR-155 had a higher risk
of death compared to patients with low expression of
these microRNAs [9,10], and miR-181b can predict time
to treatment, acting as a biomarker of progression [11].
MicroRNA signatures can also predict refractoriness to
fludarabine [7]. MiR-148a, miR-222, and miR-21 exhib-
ited a higher expression in non-responders while lower
levels of miR-34a were observed in resistant subjects
even in absence of p53 aberrations [12]. Recent studies
demonstrated that microRNAs are involved in an intri-
cate interplay with BCR signaling and microenvironmen-
tal stimuli. Indeed, BCR signaling and immunoglobulin
production can be regulated by microRNAs [13] while
the expression of certain microRNAs can be altered via
BCR stimulation [5]. A signature of 39 differentially
expressed miRNAs was found upon BCR stimulation
[14]. BCR activation can lead to reduced levels of miR-
29c, miR-150, miR-181b, or miR-223 [15], and low ex-
pression of these microRNAs was observed in patients
with shorter survival and/or time to treatment [16].
MiR-155 is instead upregulated in response to BCR
ligation and appears to play a role during T- and B-cell
development [5,13]. Recent reports proposed that miR-
NAs are released by donor cells through circulatingThis is an Open Access article distributed under the terms of the Creative
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present in the plasma of CLL patients at different levels
from healthy controls. Since therapy often reduced the
pool of malignant cells but does not affect plasma fea-
tures, it is likely that MVs continue to induce abnormal
gene profiles. Therefore, miRNA profiling in plasma
could reflect another mechanism of malignant B-cell
proliferation [17].
Role of microRNAs in CLL
Recently, researchers have focused on the molecular im-
pact of deregulation of microRNA expression in CLL.
MiR-15/16 cluster, miR-34b/c, miR-29, miR-181b, miR-
17/92, miR-150, and miR-155 family members, the most
deregulated microRNAs in CLL, were found to regulate
important genes, helping to clarify molecular steps of
disease onset/progression.
MicroRNA-15a/16-1
In 2002, a cluster of two microRNA genes, miR-15a and
miR-16-1, was located within the 13q14.3 deleted region
[18]. 13q14.3 deletion in CLL, the most frequent gen-
omic aberration, associates with the longest treatment-
free interval [19]. Accordingly, miR-15a/16-1 expression
was found downregulated in ~66% of CLL cases [18].
The importance of miR-15a/16-1 was confirmed in a
study in New Zealand black (NZB) mice, the only mouse
strain that naturally develops CLL [20]. A point muta-
tion causing a decrease of miR-16-1 expression in NZB
lymphoid tissues and elevated levels of Bcl-2 was found
in the miR-15a/16-1 precursor (located in the mouse
genomic region homologous to 13q14) [20]. B-cell
lymphoma 2 (BCL2) is a central player in the genetic
program of eukaryotic cells, promoting survival by inhi-
biting apoptosis [21], and it is overexpressed in many
human cancers [22]. MiR-15a/16-1 and BCL2 expression
levels were found inversely correlated in CLL [23], and
downregulation of these microRNAs in leukemic cell
lines resulted in an increase of Bcl2 expression with con-
sequent inhibition of apoptosis [23]. Moreover, micro-
array experiments performed on CLL patients with high
vs low levels of miR-15a/16-1 identified a gene signature
which also contains MCL1, an antiapoptotic BCL-2 fam-
ily member associated with B-CLL cell survival and
chemotherapy resistance [24].
The first genetic manipulation in mice that confirmed
the importance of miR-15a/16-1 deletion in CLL was
carried out by Dr. Dalla-Favera and colleagues [25].
These authors designed a model with conditional alleles
that either resembled the loss of the minimal deleted re-
gion (Mdr), spanning entirely the host gene Dleu2 gene
[26], or the specific miR-15a/16-1 cluster deletion, with-
out altering the expression of Dleu2 [25]. Mdr knockout
(KO) animals lived less than wild-type (WT) siblings andsuccumbed to leukemia, while the differential survival be-
tween miR-15a/16-1 KO and their WT littermates was
not statistically significant, indicating that the latter were
affected by a milder phenotype than the former [25].
Additional factors regulate miR-15a/16-1 expression
besides chromosomal deletion. Veronese et al. identified
an allele-specific transcription mechanism. Normally,
one allele of miR-15a/16-1 is transcribed by RNA poly-
merase II together with DLEU2 and the other by RNA
polymerase III independently of the host gene. In 13q14
deleted patients, exclusive RNA polymerase III-driven
transcription was observed and found to associate with
high expression of ZAP70. Indeed, in a CLL case of
monozygotic twins that differed in ZAP70 status and
clinical features, transcription of primiR-15a/16-1 was
driven by RPIII in the aggressive ZAP70-positive patient
and by RPII in the indolent ZAP70-negative case [27].
Furthermore, CLL cells show a reduced amount of proc-
essed intermediates pre-miR-15a/16-1, while the precur-
sor pri-miR-15a/16-a was not decreased, indicating a
block of miRNA maturation at the DROSHA processing
step. Interestingly, the mRNA levels of pri-miRNA pro-
cessing cofactors were not decreased, and CLL cells
retained the ability to cleave other microRNA precur-
sors, suggesting that DROSHA processing is specifically
impaired for mir-15a/16-1 and possibly other specific
miRNAs [28]. Lastly, the two copies of the critical region
were found to replicate asynchronously. Differential rep-
lication timing represents an early epigenetic mark
resulting in different chromatin packaging and monoalle-
lic expression. These findings support a model of consecu-
tive inactivation of both alleles by a series of different
mechanisms, resulting in a final complete inactivation. In-
deed, in the majority of CLLs, monoallelic deletion is suffi-
cient for complete loss of mir-15a/16-1 function rather
than a twofold downregulation. Inactivation of the active
chromosome copy by epigenetic mechanisms could there-
fore be a tumor-initiating event [29].
MicroRNA-34b/c and microRNA-34a
11q deleted region includes the miR-34b/c cluster locus
[30], while deletion of 17p leads to abrogation of the p53
tumor suppressor [31], and 13q deletion involves miR15a/
16-1 downregulation. To verify possible interactions be-
tween these chromosomal alterations, we investigated if
the miR-15a/16-1 cluster, tumor protein p53, and miR-
34b/c cluster are connected in a molecular pathway that
could explain the prognostic implications of 11q, 17p, and
13q deletions in CLL [32]. Several TP53 binding sites were
found upstream miR-15a/16-1 on chromosome 13, miR-
34b/c on chromosome 11, and miR-34a on chromosome
1. Thus,TP53 could induce the expression of these micro-
RNAs [32]. Besides, miR-15a/16-1 target TP53 while miR-
34 targets ZAP-70 mRNA expression [32]. In 13q deleted
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balance not only toward higher levels of anti-apoptotic
Bcl2 [10,23] but also toward higher levels of pro-apoptotic
p53. Consequently, the number of apoptotic cells de-
creases because of the lower level of Bcl2, but the intact
p53 pathway keeps the tumor growth relatively low. This
finding could explain how 13q deletions associate with in-
dolent CLL. Moreover, increased p53 levels in patients
with 13q deletions associate with transactivation of miR-
34b/c leading to reduced levels of ZAP-70, positively cor-
relating with survival [3]. CLL patients with 11q deletion,
instead, show lower levels of miR-34b/c and higher levels
of ZAP-70. In these patients, TP53 is not upregulated be-
cause miR-15a/16-1 are not deleted and this condition is
associated with lower control on apoptosis. TP53 transac-
tivation of miR-34b/c is ineffective, since the locus isFigure 1 Interplay between microRNA expression and chromosomal adeleted, leading to a higher expression of ZAP-70 which
correlates with poor prognosis [32] (Figure 1). 17p dele-
tion and TP53 mutation identifies the majority of
chemotherapy-resistant patients. However, almost half of
the refractory cases cannot be explained by a direct defect
of p53. Zenz et al. studied miR-34a and miR-34b/c expres-
sion in refractory CLL with and without 17p deletion or
TP53 mutation [33]. While no expression of miR-34b/c
was detected, downregulation of miR-34a was observed in
17p deleted and/or TP53 mutated cases and in fludarabine-
refractory cases even in the absence of 17p deletion/TP53
mutation. Therefore, low expression of miR-34a in CLL is
associated not only with p53 inactivation but also with
chemotherapy-refractory disease, impaired DNA damage
response, and apoptosis resistance, regardless of 17p dele-
tion/TP53 mutation [33].berration in CLL.
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In both indolent and aggressive CLLs, miR-29 is overex-
pressed when compared to normal B cells while miR-
181b is downregulated when compared to normal B
cells. Although, when comparing indolent and aggressive
CLLs, both mir-29 and mir-181b show higher expression
levels in indolent cases [34-36]. Moreover, miR-181b ex-
pression is decreased during CLL progression when se-
quential samples from the same patients are compared
[11]. In the same study, miR-181b is also reported to tar-
get MCL1 in CLL, while in another study on human gas-
tric and lung cancer cell lines, it was found able to
target BCL2 and involved in the development of multi-
drug resistance [37]. To clarify the role of miR-29 in
CLL, we designed a transgenic mouse model and mice
overexpressing miR-29 developed a disease similar to the
indolent form of CLL. The role of downregulation of
miR-29 and miR-181b in aggressive CLLs appears to cor-
relate with Tcl1 overexpression [35]. Activation of TCL1
oncogene (T cell leukemia/lymphoma 1) is a central
event in the initiation of aggressive CLL, and high Tcl1
expression correlates with aggressive phenotype [38].
We verified that coexpression of TCL1 with miR-29 and
miR-181 decreased its expression and found inverse cor-
relation between miR-29b, miR-181b, and Tcl1 expression
in CLL samples [35].
MicroRNA-17/92
MiR-17/92 is a polycistronic microRNA cluster overex-
pressed in several lymphoid malignancies. In 2008, Xiao
et al. [39] generated mice with higher expression of miR-
17/92 in lymphocytes. These mice developed lymphopro-
liferative disease and autoimmunity and died prematurely.
Lymphocytes from these mice showed more proliferation
and less apoptosis. MiR-17/92 inhibited the expression of
the tumor suppressor PTEN and the proapoptotic protein
Bim. These data indicate that PTEN and Bim were direct
targets of miR-17/92 cluster molecules [39].
A recent study demonstrated that BCR signals can
modulate expression of microRNAs. Evidence that BCR
response in aggressive UM-IgH VH CLL is accomplished
through upregulation of miR-17/92 has been described. In
this study, the BCR-driven induction of miR-17/92 in UM-
IgH VH CLLs was proposed as possible regulator of B-cell
proliferation/survival by downregulating anti-proliferative
and/or pro-apoptotic genes [40].
To determine whether miR-17/92 overexpression in-
duces lymphomagenesis, we generated a transgenic mouse
overexpressing miR-17/92 in B cells [41]. Eighty percent
of mir-17/92 transgenics developed a B-cell malignancy
characterized by expansion of CD19+ B cells. Forty-four
microRNAs and 680 genes were differentially expressed in
these malignant B cells compared to controls. Eight up-
regulated miRs were correlated with 101 downregulatedtarget mRNAs, and 11 downregulated miRs were corre-
lated with 66 upregulated target mRNAs. ABCC3, a
member of the ABC transporter family involved in anti-
cancer agents transport, phosphoinositide 3-kinase
(PI3K), growth arrest, and DNA damage 45 (GADD45),
IL-4 were among downregulated mRNAs in miR-17/92
mice [41].
MicroRNA-155
MiR-155 and BIC, its host gene, have been reported to
accumulate in human B-cell lymphomas, especially in
diffuse large B-cell lymphomas, Hodgkin lymphomas,
and certain types of Burkitt lymphomas [42]. To study
its role in B-cell development and lymphomagenesis, we
generated a transgenic mouse expressing mmu-miR-155
in B cells [42]. We showed that Eμ-mmu-miR-155 mice
exhibit initially a preleukemic pre-B-cell proliferation
evident in the spleen and bone marrow, followed by
frank B-cell malignancy resembling the human diseases.
These findings indicate that miR-155 is able to induce
polyclonal expansion, favoring the capture of secondary
genetic changes for full transformation and suggests that
miR-155 is directly implicated in the initiation and/or
progression of these diseases [42].
It has been reported that expression of miR-155 can
alter the signaling pathways triggered by BCR response
by modulating the expression of SHIP1 in CLL. SHIP1
encodes for Src homology-2 domain containing inositol
5-phosphatase 1, a phosphatase that may suppress sur-
face immunoglobulin and BCR signaling. SHIP1 is a pre-
dicted target of miR-155, and transfection experiments
confirmed the targeting by reducing its expression and
enhancing cell sensitivity to BCR stimulation. Survival
signals from auxiliary cells in the microenvironment
might contribute to the upregulation of miR-155. Indeed,
T cells or accessory cells of the lymphoid tissue can
enhance expression of miR-155 by stimulating the BCR
response via CD154/CD40 or BAFF/APRIL interaction
and in vitro CLL cells stimulated with CD154 or BAFF/
APRIL show reduced expression of SHIP1 and enhanced
responsiveness to BCR ligation. Similar effects were also
noted in normal B cells, indicating that miR-155 might
play a physiologic role in regulating the B-cell response
to BCR ligation [13].
Another microenvironmental system that has recently
been studied is represented by the role of microvescicles
(MVs) in intercellular communication [6]. Recently, Fer-
rajoli et al. [17] hypothesized that some miRNAs might
be involved in the transition from monoclonal B-cell
lymphocytosis (MBL) to CLL and that these miRNAs
may also predict response to therapy. They found miR-155
increasingly overexpressed both in cells and in circulating
microvesicles (MVs) from normal to MBL and CLL
samples. Furthermore, miR-155 expression was higher
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plasma level of miR-155 was lower in patients who
achieved complete remission than in patients who ex-
perienced other responses. These data validate the
ability of miR-155 to predict response to treatment and
suggest that increasingly higher expression of miR-155
from normal B cells to MBL to CLL and its overexpres-
sion in the plasma can be used as a predictor for poor
response to treatment and disease progression.Conclusions
The ability of microRNAs to modulate gene expression is
essential to provide fine control on several cell processes
and its deficiency can be involved in CLL development/
progression. Indeed, their deregulation can affect down-
stream pathways on cell cycle and proliferation. MiR-15a/
16-1 deletion is an initializing step in CLL, eliciting the
control on Bcl2 expression. MiR-34 family members are
involved in a fine-regulated feedback circuitry with p53
and miR-15a/16-1 in 13q deleted CLL, suggesting bidirec-
tional interplay between microRNAs and genes. Moreover,
restoring expression of miR-15a/16-1 indirectly affects ex-
pression of miR-34 family by modulating p53 expression
and downregulation of miR-29 and miR-181b in aggres-
sive CLL contributes to overexpression of Tcl1 [43]. Fur-
thermore, study of miR-17/92 and miR-155 may provide
useful insights into drug design, delivery, resistance mech-
anisms, and microenvironmental responses [17,41]. BCR
stimulation can alter the expression of certain micro-
RNAs, and BCR-regulated microRNAs might affect B-cell
proliferation and apoptosis [14]. Further studies could aim
to develop new therapies that disrupt the capacity of CLL
cells to home to tissue microenvironments or that inhibit
the signaling from accessory cells within the microenvir-
onment. For example, agents that block the capacity of
CLL cells to engage accessory cells might be expected to
decrease the levels of miR-155, which increases cell sen-
sitivity to BCR [13]. Lastly, deregulation of microRNAs
can originate from chromosomal alteration, epigenetic
modulation, allele selection, aberrant precursor processing,
or interaction with other genes. Given these results, we
can underline that microRNAs have a deep impact on
CLL development/progression.Competing interests
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